Hyperaldosteronism (benign or malignant) — VA Rating Criteria (38 CFR DC 7917)

The VA rates Hyperaldosteronism (benign or malignant) under Diagnostic Code 7917 at the following tiers: 0%. The minimum 0% rating requires: Note: Evaluate as malignant or benign neoplasm, as appropriate.. The maximum 0% rating requires: Note: Evaluate as malignant or benign neoplasm, as appropriate..

Diagnostic Code 7917 is the VA rating identifier for Hyperaldosteronism (benign or malignant) within 38 CFR 38 CFR § 4.119. It defines the specific symptom criteria and percentage thresholds a VA adjudicator uses to assign a disability rating. The diagnostic code is listed on a veteran's rating decision letter.

The maximum rating for Hyperaldosteronism (benign or malignant) is defined in 38 CFR Part 4 under DC 7917. See the rating tiers above for exact criteria.

Hyperaldosteronism (benign or malignant) is rated under 38 CFR 38 CFR § 4.119, Diagnostic Code 7917. This section is part of the Schedule for Rating Disabilities (38 CFR Part 4) and can be read in full at the eCFR website.

Secondary conditions caused or aggravated by Hyperaldosteronism (benign or malignant) may be ratable under 38 CFR § 3.310. Veterans should work with a VSO or accredited claims agent to document the medical relationship.

Service connection for Hyperaldosteronism (benign or malignant) requires three elements: (1) a current diagnosis of the condition, (2) an in-service event, injury, or disease that may have caused or aggravated it, and (3) a medical nexus connecting the current diagnosis to that in-service event. A nexus letter from a treating physician or independent medical examiner is the most reliable nexus evidence. C&P exam findings can also establish nexus if adequately documented.